CIK 0001635088 · Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- operating
- EIN
- 981173944
- Phone
- 441-295-5950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $74,439,518
- in 11 filings, $37.9M under 10b5-1 plans
Net −$74,439,518. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-03 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $36.31 | $7.3M | 999,154 |
| 2026-10-28 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $36.59 | $7.3M | 1,199,154 |
| 2026-10-23 | Epperly Melissa B, Director | Grant or award | +513 | 15,467 | ||
| 2026-10-23 | Epperly Melissa B, Director | Shares withheld for taxes | −116 | $36.49 | $4K | 15,351 |
| 2026-10-23 | Oren Ilan Director | Grant or award | +810 | 124,490 | ||
| 2026-10-23 | MOMTAZEE JAMES C Director | Grant or award | +383 | 112,342 | ||
| 2026-10-23 | MOMTAZEE JAMES C Director | Shares withheld for taxes | −77 | $36.49 | $3K | 112,265 |
| 2026-10-20 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −185,856 | $35.09 | $6.5M | 1,413,298 |
| 2026-10-20 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −14,144 | $35.42 | $501K | 1,399,154 |
| 2026-10-16 | Sukhatme Mayukh President & CIO | Shares withheld for taxes | −19,976 | $33.53 | $670K | 18,563,884 |
| 2026-10-16 | Gline Matthew CEO | Shares withheld for taxes | −34,638 | $33.53 | $1.2M | 16,549,136 |
| 2026-10-01 | Epperly Melissa B, Director | Option exercise 10b5-1 | +17,750 | $4.46 | $79K | 32,704 |
| 2026-10-01 | Epperly Melissa B, Director | Sale 10b5-1 | −16,850 | $36.08 | $608K | 15,854 |
| 2026-10-01 | Epperly Melissa B, Director | Sale 10b5-1 | −900 | $36.57 | $33K | 14,954 |
| 2026-10-01 | Epperly Melissa B, Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −17,750 | 151,416 | ||
| 2026-09-30 | Sukhatme Mayukh President & CIO | Shares withheld for taxes | −46,879 | $36.57 | $1.7M | 18,583,860 |
| 2026-09-30 | Venker Eric President & Immunovant CEO | Option exercise 10b5-1 | +200,000 | $3.85 | $770K | 1,799,154 |
| 2026-09-30 | Venker Eric President & Immunovant CEO | Sale 10b5-1 | −200,000 | $36.62 | $7.3M | 1,599,154 |
| 2026-09-30 | Venker Eric President & Immunovant CEO | Option exercise · Stock Option (Right to Buy) 10b5-1 | −200,000 | 3,644,834 | ||
| 2026-09-30 | Gline Matthew CEO | Shares withheld for taxes | −76,171 | $36.57 | $2.8M | 16,583,774 |
Page 1 of 15 · 281 trades